5 Things You Need to Know From Bristol-Myers Squibb's Q2 Earnings Update
It hasn't been a great year for Bristol-Myers Squibb (NYSE: BMY) so far. Despite posting solid first-quarter results in April, the big pharma company's shares have dropped close to 16%. Investors have been concerned about Opdivo's growth prospects. Many remain skeptical about the drugmaker's pending acquisition of Celgene (NASDAQ: CELG).
BMS announced its second-quarter earnings results before the market opened on Thursday. Did these results change perceptions about the company? Maybe a little. The company shared some good news that investors should like. Here are five things you need to know from Bristol-Myers Squibb's Q2 earnings update.
Image source: Getty Images.
Quelle Fool.com
